ERBB2 and breast carcinoma: All three drugs were first approved for advanced hormone positive HER2 negative breast cancer patients in combination with hormone therapy (letrozole with palbociclib or ribociclib, and fulvestrant/abemaciclib), for which they presented synergistic growth inhibitory activity.